Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-07-05
2011-07-05
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S143100, C514S266200, C514S266210, C530S387900, C530S388220, C544S284000
Reexamination Certificate
active
07972600
ABSTRACT:
The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.
REFERENCES:
patent: 4774321 (1988-09-01), Rosner et al.
patent: 5200509 (1993-04-01), Spencer et al.
patent: 5262308 (1993-11-01), Baserga
patent: 5597563 (1997-01-01), Beschorner
patent: 5624805 (1997-04-01), Spencer et al.
patent: 5670341 (1997-09-01), Spencer et al.
patent: 5681818 (1997-10-01), Spencer et al.
patent: 5688505 (1997-11-01), Webb et al.
patent: 5705157 (1998-01-01), Greene
patent: 5798266 (1998-08-01), Quay et al.
patent: 5852174 (1998-12-01), Vlassara et al.
patent: 5869337 (1999-02-01), Crabtree et al.
patent: 5872220 (1999-02-01), Kiefer et al.
patent: 5891722 (1999-04-01), Fuks et al.
patent: 5939269 (1999-08-01), Goldfine et al.
patent: 5942412 (1999-08-01), Prager et al.
patent: 5968508 (1999-10-01), Goldfine
patent: 5968758 (1999-10-01), Fuks et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 5993818 (1999-11-01), Torchilin et al.
patent: 6071891 (2000-06-01), Low et al.
patent: 6084085 (2000-07-01), Baserga et al.
patent: 6090383 (2000-07-01), Dasch et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6368826 (2002-04-01), Ligensa et al.
patent: 6875741 (2005-04-01), Pillutla et al.
patent: 7037498 (2006-05-01), Cohen et al.
patent: 7071160 (2006-07-01), Yamano et al.
patent: 7071300 (2006-07-01), Deshayes et al.
patent: 7217796 (2007-05-01), Wang et al.
patent: 7241444 (2007-07-01), Goetsch et al.
patent: 7300655 (2007-11-01), Hansen et al.
patent: 7329745 (2008-02-01), Fujita-Yamaguchi
patent: 7371378 (2008-05-01), Cohen et al.
patent: 7432244 (2008-10-01), Deshayes et al.
patent: 7598350 (2009-10-01), Liu et al.
patent: 7638605 (2009-12-01), Ludwig
patent: 2003/0021780 (2003-01-01), Smith et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0235582 (2003-12-01), Singh et al.
patent: 2004/0018191 (2004-01-01), Wang et al.
patent: 2004/0057950 (2004-03-01), Waksal et al.
patent: 2004/0102360 (2004-05-01), Barnett et al.
patent: 2004/0116330 (2004-06-01), Naito et al.
patent: 2004/0141958 (2004-07-01), Steinaa et al.
patent: 2004/0202651 (2004-10-01), Cohen et al.
patent: 2004/0202655 (2004-10-01), Morton et al.
patent: 2004/0214898 (2004-10-01), Steiner et al.
patent: 2004/0228859 (2004-11-01), Graus et al.
patent: 2004/0265307 (2004-12-01), Singh et al.
patent: 2005/0008642 (2005-01-01), Graus et al.
patent: 2005/0079184 (2005-04-01), Hsing-Chang et al.
patent: 2005/0084906 (2005-04-01), Goetsch et al.
patent: 2005/0136063 (2005-06-01), Wang et al.
patent: 2005/0164970 (2005-07-01), Li
patent: 2005/0186203 (2005-08-01), Singh et al.
patent: 2005/0244408 (2005-11-01), Cohen et al.
patent: 2005/0249728 (2005-11-01), Singh et al.
patent: 2005/0249730 (2005-11-01), Goetsch et al.
patent: 2005/0281812 (2005-12-01), Cohen et al.
patent: 2006/0088539 (2006-04-01), Bander
patent: 2006/0106203 (2006-05-01), Winter et al.
patent: 2006/0134172 (2006-06-01), Shepard et al.
patent: 2006/0149033 (2006-07-01), Deshayes et al.
patent: 2006/0193772 (2006-08-01), Ochiai et al.
patent: 2006/0233814 (2006-10-01), Goldmakher et al.
patent: 2007/0009970 (2007-01-01), Heller et al.
patent: 2007/0010537 (2007-01-01), Hamamura et al.
patent: 2007/0196376 (2007-08-01), Raeber et al.
patent: 2009/0110678 (2009-04-01), Ludwig et al.
patent: 0294021 (1988-12-01), None
patent: 0369943 (1990-05-01), None
patent: 0375438 (1990-06-01), None
patent: 8906692 (1989-07-01), None
patent: 96/30347 (1996-10-01), None
patent: 96/40210 (1996-12-01), None
patent: 9744352 (1997-11-01), None
patent: 9825642 (1998-06-01), None
patent: 99/08668 (1999-02-01), None
patent: 01/90192 (2001-11-01), None
patent: 02053596 (2002-07-01), None
patent: 03059951 (2003-07-01), None
patent: 03100008 (2003-12-01), None
patent: 03106621 (2003-12-01), None
patent: 2004071529 (2004-08-01), None
patent: 2004083248 (2004-09-01), None
patent: 2004087756 (2004-10-01), None
patent: 2005005635 (2005-01-01), None
patent: 2005016970 (2005-02-01), None
patent: 2005052005 (2005-06-01), None
patent: 2005/090407 (2005-09-01), None
patent: 2005082415 (2005-09-01), None
patent: 2006008639 (2006-01-01), None
patent: 2006/020258 (2006-02-01), None
patent: 2006013472 (2006-02-01), None
patent: 2006060419 (2006-06-01), None
patent: 2006069202 (2006-06-01), None
patent: 2007000328 (2007-01-01), None
patent: 2007012614 (2007-02-01), None
patent: 2007031875 (2007-03-01), None
Hellawell, et al., Cancer Research 6:2942-2950 (2002).
Nickerson, et al., Cancer Research 61:6276-6280 (2001).
Burtrum, et al., Cancer Res. 63:8912-8921 (2003).
Corey, et al., Prostate 99:392-401 (2003).
Greenman, et al., Nature 446(8):153-158 (2007).
Li, et al., Can. Immunol. Immunother. 49:243-252 (2000).
Tennant, et al., Prostate 56:115-122 (2003).
Wu, et al., Clin. Cancer Res. 11:3065-3074 (2005).
Yu, et al., Natl. Cancer Inst. 92:1472-1489 (2000).
Adams, et al., Cell. Mol. Life Sci. 57:1050-1093 (2000).
Baserga, Oncogene 19:5574-5581 (2000).
Batley, et al., Life Sci. 62:143-150 (1998).
Bonifacino, et al., Current Protocols in Cell Biology, Wiley & Sons (1999).
Coligan, et al., Current Protocols in Immunology, Wiley & Sons, Inc. (1991).
Collins, Glia 15:289-296 (1995).
de Hoon, et al., Bioinformatics 20:1453-1454 (2004).
Elbashir, et al., Nature 411:494-498 (2001).
Enna, et al., Current Protocols in Pharmacology, Wiley & Sons (1991).
Freireich, et al., Cancer Chemother. Rep. 50(4):219-245 (1966).
Ganesan, Drug Discov. Today 7(1):47-55 (2002).
Garcia-Echeverria, et al., Cancer Cell 5:231-239 (2004).
Geller, et al., J. Urol. 132:693-700 (1984).
Girnita, et al., Cancer Res. 64:236-242 (2004).
Grandis, et al., Cancer 78:1284-1292 (1996).
Haluska, et al., Cancer Res. 66:362-371 (2006).
Hoffmann, et al., Anticancer Res. 17:4419-4426 (1997).
Khvorova, Cell 115:209-216 (2003).
Lou, Drug. Discov. Today 6(24):1288-1294 (2001).
Mello, et al., Nature 431:338-342 (2004).
Mitsiades, et al., Cancer Cell 5:221-230 (2004).
Moyer, et al., Cancer Res. 57:4838-4848 (1997).
Nelson, et al., Nucl. Acids Res. 30(1):218-220 (2002).
O'Connor, et al., Horm. Metub. Res. 35:771-777 (2003).
Paddison, et al., Curr. Opin. Mol. Ther. 5:217-224 (2003).
Page, Comput. Appl. Biosci., 12:357-358 (1996).
Pandini, et al., Clin. Can. Res. 5:1935-1944 (1999).
Panek, et al., J. Pharmacol. Exp. Thera. 283:1433-1444 (1997).
Parrizas, et al., Endocrinology 138(4):1427-1433 (1997).
Petrides, et al., Cancer Res. 50:3934-3939 (1990).
Pollack, et al., J. Pharmacol., 291:739-748 (1999).
Radinsky, et al., Clin. Cancer Res. 1:19-31 (1995).
Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press (1989).
Sauter, et al., Am. J. Path., 148:1047-1053 (1996).
Sazani, et al., J. Clin. Invest. 112:481-486 (2003).
Shimizu, et al., Japan J. Cancer Res. 85:567-571 (1994).
Siddle, et al., The IGF System, Humana Press, pp. 199-225 (1999).
Tusher, et al., Proc. Natl. Acad. Sci. USA 98(9):5116-5121 (2001).
Wikstrand, et al., Cancer Res. 55:3140-3148 (1995).
Williams, Biochem. Soc. Trans. 25:509-513 (1997).
Wittman, et al., J. Med. Chem. 48:5639-5643 (2005).
Wraight, Nat. Biotechnol. 18:521-6 (2000).
Wu, et al., Clin. Cancer Res. 12(20):6153-6160 (2006).
Zamecnik, et al., Proc. Natl. Acad. Sci. USA 75(1):280-284 (1978).
Zhang, et al., Oncogene 24:2474-2482 (2005).
Burfeind, et al., PNAS 93(14):7263-7268 (1996).
Hofmann, et al., Drug Disc. Today 10(15)—1041-1047 (2005).
Wang, et al., Curr. Can. Drug Targets 2(3):191-207 (2002).
Wang, et al., Mol. Can. Ther. 4(8):1214-1221 (2005).
Plymate, et al., Clin. Can. Res. 13(21):6429-6439 (2007).
Ludwig Dale L.
Plymate Stephen R.
ImClone LLC
Jivraj Sanjay
University of Washington
Woods Nicole S.
Zara Jane
LandOfFree
IGF-IR antagonists as adjuvants for treatment of prostate... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IGF-IR antagonists as adjuvants for treatment of prostate..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IGF-IR antagonists as adjuvants for treatment of prostate... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674485